References
- Joppi R, Bertele’ V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013;69(4):1009-24
- Vegter S, Rozenbaum MH, Postema R, et al. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Clin Ther 2010;32(9):1651-61
- Güngör D, De Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011;6(1):34
- Kanters TA, Hagemans ML, Van der Beek NA, et al. Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis 2011;34:1045-52
- Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66(3):329-35
- Van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010;362(15):1396-406
- Güngör D, Kruijshaar ME, Plug I, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013;8(1):49
- Scottish Medicines Consortium. Alglucosidase alfa 50mg powder for concentrate for solution for infusion (Myozyme) No. (352/07). 2007
- All Wales Medicines Strategy Group. Use of alglucosidase alfa (Myozyme) within NHS Wales. 2006
- National Specialised Commissioning Advisory Group. Policy on the funding of enzyme replacement therapy and substrate reduction therapy. 2008
- Transparency Committee. Myozyme 50mg, powder for concentrate for solution for infusion. 2013
- Agenzia Italiano Del Farmaco. Reimbursement and pricing of the specialized medicine for human use «Myozyme» (recombinant human a-glucosidase acid) authorized by the centralized European procedure by European Commission (Determination/C n. 111/06). [in Italian]. Gazetta Ufficiale 2006;273
- Denis A, Simoens S, Fostier C, et al. Policy for rare diseases and orphan drugs. 2009;112A
- Kanters TA, Redekop WK, Hakkaart L. Factors predicting reimbursement decisions on orphan drugs in eight countries. Value Health 2012;15(7):A308
- Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68(2):99-109
- Winkel LP, Van den Hout JM, Johanna MP, et al. Enzyme replacement therapy in late-onset Pompe’s disease: A three-year follow-up. Ann Neurol 2004;55(4):495-502
- Williams A. Intergenerational equity: an exploration of the’fair innings’ argument. Health Econ 1997;6(2):117-32
- McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003;56(12):2407-19
- Bobinac A, van Exel NJ, Rutten FF, et al. Inquiry into the Relationship between Equity Weights and the Value of the QALY. Value Health 2012;15(8):1119-26
- Mirelman A, Mentzakis E, Kinter E, et al. Decision-making criteria among national policymakers in five countries: a discrete choice experiment eliciting relative preferences for equity and efficiency. Value Health 2012;15(3):534-9